0000950170-24-042291.txt : 20240405 0000950170-24-042291.hdr.sgml : 20240405 20240405163014 ACCESSION NUMBER: 0000950170-24-042291 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240402 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240405 DATE AS OF CHANGE: 20240405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 24826908 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 8-K 1 adpt-20240402.htm 8-K 8-K
0001478320False00014783202024-04-022024-04-02

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 2, 2024

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

Washington

001-38957

27-0907024

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

1165 Eastlake Avenue East

Seattle, Washington

98109

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ADPT

 

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02

Results of Operations and Financial Condition.

On April 2, 2024, Adaptive Biotechnologies Corporation (the “Company”) issued a press release that included, among other things, preliminary financial results for the quarter ended March 31, 2024. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

99.1

Press Release dated April 2, 2024

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Adaptive Biotechnologies Corporation

Date: April 5, 2024

By:

/s/ Chad Robins

Chad Robins

Chief Executive Officer

 

 

 EX-99.1 2 adpt-ex99_1.htm EX-99.1 EX-99.1

EXHIBIT 99.1

img119828894_0.jpg 

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

 

Announces CFO transition

 

SEATTLE, April 02, 2024 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a business update, including the conclusion of its recent strategic review, preliminary revenue for the first quarter ended March 31, 2024, and transition of the chief financial officer role.

Strategic Review Update

After evaluating a number of potential opportunities as part of the strategic review, Adaptive’s management team and board of directors concluded that the current best outcome to maximize shareholder value is to operate the MRD and Immune Medicine businesses internally within Adaptive while increasing their independence from one another by restructuring each business with dedicated resources and separate segment reporting. Importantly, under this structure, Adaptive preserves its strong capital position which will bridge the MRD business to profitability and support targeted investments in Immune Medicine.

Management will provide further details on the process and outcome of the strategic review during the conference call this afternoon.

First Quarter 2024 Preliminary Unaudited Revenue Results

•
Total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023.
•
MRD revenue of approximately $31 to $32 million for the first quarter of 2024, an increase of approximately 47% compared to the first quarter of 2023.

CFO Transition

Adaptive Biotechnologies announced that Tycho Peterson, chief financial officer (CFO), will be departing the company to pursue another opportunity. Kyle Piskel, who currently serves as the company’s Principal Accounting Officer and has held various financial roles at Adaptive over the past 8 years, will succeed Tycho as full-time CFO. Kyle previously served as the company’s Interim CFO from February to June 2022 and brings over 15 years of financial expertise to the role.

“I am excited to announce Kyle as our new chief financial officer,” said Chad Robins, chief executive officer and co-founder, Adaptive Biotechnologies. “I am confident he has the business knowledge to operate and execute, with the necessary guardrails in place, so that our team can maximize the full value of both MRD and Immune Medicine businesses. I would like to thank Tycho for his financial leadership and significant contributions to Adaptive over the past two years, including his leadership during the strategic review process. We wish him success in his next endeavor.”

 

“I’m proud of the great work we accomplished together through a critical time in the company’s evolution over the past two years,” said Tycho Peterson, chief financial officer, Adaptive Biotechnologies. “Adaptive has a bold vision and world class science and is just beginning to unlock the potential on both its MRD and Immune Medicine businesses. I am confident in the future prospects of the business, and I look forward to following Adaptive’s continued progress and success.”

Webcast and Conference Call Information

Adaptive Biotechnologies will host a conference call to discuss its business updates after market close on Tuesday, April 2, 2024 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. The conference call can be accessed at http://investors.adaptivebiotech.com. The webcast will be archived and available for replay at least 90 days after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

 

Important Note Regarding Preliminary, Unaudited Financial Results

Adaptive Biotechnologies has not completed the preparation of its financial statements for the first quarter of 2024. The financial disclosures referenced in this release for the first quarter are preliminary and are thus inherently uncertain and subject to change as we complete our financial close processes for the first quarter of 2024. Adaptive Biotechnologies is in the process of completing its customary quarter-end close and review procedures as of and for the quarter ended March 31, 2024, and there can be no assurance that final results for this period will not differ from these estimates.

Forward-Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations

201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications

206-279-2423
media@adaptivebiotech.com

 GRAPHIC 3 img119828894_0.jpg GRAPHIC begin 644 img119828894_0.jpg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end EX-101.SCH 4 adpt-20240402.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Pre Commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation State Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Cover Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Securities Act File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Security 12b Title Document Type Document Type XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document and Entity Information
Apr. 02, 2024
Cover [Abstract]  
Entity Registrant Name ADAPTIVE BIOTECHNOLOGIES CORPORATION
Amendment Flag false
Entity Central Index Key 0001478320
Document Type 8-K
Document Period End Date Apr. 02, 2024
Entity Incorporation State Country Code WA
Entity File Number 001-38957
Entity Tax Identification Number 27-0907024
Entity Address, Address Line One 1165 Eastlake Avenue East
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98109
City Area Code (206)
Local Phone Number 659-0067
Written Communications false
Soliciting Material false
Pre commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol ADPT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports adpt-20240402.htm adpt-20240402.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "adpt-20240402.htm": { "nsprefix": "adpt", "nsuri": "http://www.adaptivebiotech.com/20240402", "dts": { "inline": { "local": [ "adpt-20240402.htm" ] }, "schema": { "local": [ "adpt-20240402.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_17d8b7bd-9180-49c2-ac27-35baadd61b1b", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "adpt-20240402.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_17d8b7bd-9180-49c2-ac27-35baadd61b1b", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "adpt-20240402.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation State Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre Commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.adaptivebiotech.com/20240402/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-042291-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-042291-xbrl.zip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end XML 16 adpt-20240402_htm.xml IDEA: XBRL DOCUMENT 0001478320 2024-04-02 2024-04-02 0001478320 false 8-K 2024-04-02 ADAPTIVE BIOTECHNOLOGIES CORPORATION WA 001-38957 27-0907024 1165 Eastlake Avenue East Seattle WA 98109 (206) 659-0067 false false false false Common stock, par value $0.0001 per share ADPT NASDAQ false